𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recurrent breast cancer: Factors influencing survival, including treatment

✍ Scribed by N. W. Pearlman; P. R. Jochimsen


Publisher
John Wiley and Sons
Year
1979
Tongue
English
Weight
434 KB
Volume
11
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis


Factors influencing survival were reviewed in 464 patients with recurrent breast cancer. Site of first recurrence and rate of tumor progression governed prognosis more than choice of initial therapy. Overall median survival was 22-26 months for bone/soft-tissue disease, 10-1 2 months for pleura/lung, and 4-6 months for liver/brain recurrence. Patients with slow rates of tumor progression at each site had longer survival terms than did rapid progressors. About 50% of patients with bone or soft-tissue recurrence had slow progression and long survival, regardless of whether initial treatment was local or systemic. In visceral recurrence, the number of patients with slow progression was doubled with systemic therapy in comparison to local treatment (from 16-20% for the latter to 37-38% for the former). In addition, long-term survival in patients with similar progression rates was best using initial systemic therapy.


πŸ“œ SIMILAR VOLUMES


Factors influencing survival in bilatera
✍ Dr. Adel S. Al-Jurf; Peter R. Jochimsen; Luis F. Urdaneta; David H. Scott πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 334 KB

## Abstract One Hundred And Four Patients With Bilateral Breast Cancers, Detected Clinically, Were Studied. Patients With Synchronous Lesions Experienced The Worst Survival. Lymph Node Metastases In The Second Mastectomy Had Obvious Adverse Effect On Survival. The Development Of Scirrhous Carcinoma

Is breast cancer survival improving? : T
✍ Sharon H. Giordano; Aman U. Buzdar; Terry L. Smith; Shu-Wan Kau; Ying Yang; Gabr πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 113 KB

## Abstract ## BACKGROUND Despite advances in therapies for breast cancer, improvement in survival for patients with recurrent or metastatic breast cancer has been difficult to establish. The objective of the current study was to determine whether the survival of women with recurrent breast cancer